Drug use before and during pregnancy in Serbia

International Journal of Clinical Pharmacy

Volumn 34, Issue 5, 2012, Pages 719-727

  Odalovic, Marina ^a   Vezmar Kovacevic, Sandra ^a   Ilic, Katarina ^a   Sabo, Ana ^b   Tasic, Ljiljana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Drug use; FDA pregnancy risk classification; OTC medication; Pregnancy; Serbia

Indexed keywords

AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; ANTITUSSIVE AGENT; FOLIC ACID; GESTAGEN; NON PRESCRIPTION DRUG; PARACETAMOL; RESPIRATORY TRACT AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG CLASSIFICATION; DRUG USE; FEMALE; FIRST TRIMESTER PREGNANCY; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MATERNAL CARE; MCNEMAR TEST; PERINATAL DRUG EXPOSURE; PHARMACY; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUESTIONNAIRE; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SELF MEDICATION; SELF REPORT; SERBIA; TERATOGENICITY; THIRD TRIMESTER PREGNANCY;

ADOLESCENT; ADULT; COHORT STUDIES; FEMALE; HUMANS; PHARMACEUTICAL PREPARATIONS; PREGNANCY; QUESTIONNAIRES; SELF MEDICATION; SELF REPORT; SERBIA; YOUNG ADULT;

EID: 84867400463     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9665-8     Document Type: Article

References (33)

1. Smithells RW, Newman CGH. Recognition of thalidomide defects. J Med Genet. 1992;29(10):716-23.
2. Leck IM, Millar EL. Incidence of malformations since the introduction of thalidomide. BMJ. 1962;2(5296):16-20.
3. Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011;157C(3):175-82.
4. Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann. 2010;41(4):241-50.
5. Finnell RH. Teratology: general considerations and principles. J Allergy Clin Immunol. 1999;103(2):S337-42.
6. World Health Organization. Body mass index classification. Available at: http://apps.who.int/bmi/index.jsp?introPage=intro-3.html. Accessed on 09 June 2012.
7. World Health Organization. ATC/DDD index 2012. Available at: http://www.whocc.no/atc-ddd-index/. Accessed on 10 June 2012.
8. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 8th ed. Philadelphia: Lippincott Wiliams & Wilkins; 2008. ISBN: 978-0-7817-7876-3.
9. Sipetic T. National formulary. Belgrade: Medicines and Medical Devices Agency of Serbia; 2010.
10. De Vigan C, De Walle HEK, Cordier S, Goujard J, Knill-Jones R, Ayme S, et al. Therapeutic drug use during pregnancy: a comparison in four European countries. J Clin Epidemiol. 1999;52(10):977-82.
11. Kebede B, Gedif T, Getachew A. Assessment of drug use among pregnant women in Addis Ababa. Ethiopia. Pharmacoepidemiol Drug Saf. 2009;18(6):462-8.
12. Rohra DK, Das N, Azam SI, Solangi NA, Memon Z, Shaikh AM, et al. Drug-prescribing patterns during pregnancy in the tertiary care hospitals of Pakistan: a cross sectional study. BMC Pregnancy Childbirth. 2008;8:24-8.
13. Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HEK, De Jong-Van Den Berg LTW. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancyrelated drugs in the Netherlands. BJOG. 2006;113(5):559-68.
14. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191(2):398-407.
15. Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol. 2004;60(9):659-66.
16. Stephansson O, Granath F, Svensson T, Haglund B, Ekbom A, Kieler H. Drug use during pregnancy in Sweden - assessed by the prescribed drug register and the medical birth register. Clin Epidemiol. 2011;3(1):43-50.
17. Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106 000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol. 2008;65(5):653-60.
18. Nordeng H, Eskild A, Nesheim BI, Jacobsen G. Drug use in pregnancy among parous Scandinavian women. Norsk Epidemiologi. 2001;11:97-103.
19. Headley J, Northstone K, Simmons H, Golding J. Medication use during pregnancy: data from the Avon longitudinal study of parents and children. Eur J Clin Pharmacol. 2004;60(5):355-61.
20. Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg L, Olsen J, Sørensen HT, et al. Drug use in first pregnancy and lactation: a population-based survey among Danish women. Eur J Clin Pharmacol. 1999;55(2):139-44.
21. Malm H, Martikainen J, Klaukka T, Neuvonen PJ. Prescription drugs during pregnancy and lactation - a Finnish register-based study. Eur J Clin Pharmacol. 2003;59(2):127-33.
22. Thach TS. Progestogen for preventing miscarriage: RHL commentary. World Health Organization; 2009. Available at: http://apps.who.int/rhl/pregnancy- childbirth/antenatal-care/miscarriage/cd003511-thacht/en/index.html. Assessed on 09 June 2012.
23. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Sys Rev. 2008;2:CD003511.
24. Donati S, Baglio G, Spinelli A, Grandolfo ME. Drug use in pregnancy among Italian women. Eur J Clin Pharmacol. 2000; 56(4):323-8.
25. De-Regil LM, Fernández-Gaxiola AC, Dowswell T, Peńa-Rosas JP. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2010;10:007950.
26. European surveillance of congenital anomalies special report: prevention on neural tube defect by periconceptual folic acid supplementation in Europe. Available at: http://www.eurocat-network.eu/content/Special-Report-NTD-3rdEd- Part-I.pdf. Accessed on 10 June 2012.
27. Law R, Bozzo P, Koren G, Einarson A. FDA pregnancy risk categories and the CPS: do they help or are they a hindrance? Can Fam Physician. 2010;56(3):239-41.
28. Hardy JR, Leaderer BP, Holford TR, Hall GC, Bracken MB. Safety of medications prescribed before and during early pregnancy in a cohort of 81 975 mothers from the UK general practice research database. Pharmacoepidemiol Drug Saf. 2006;15(8): 555-64.
29. Yang T, Walker MC, Krewski D, Yang Q, Nimrod C, Garner P, et al. Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population. Pharmacoepidemiol Drug Saf. 2008;17(3):270-7.
30. Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf. 2006;15(8):546-54.
31. Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 2010;20(9):895-902.
32. Olesen C, Søndergaard C, Thrane N, Nielsen GL, de Jong-van den Berg L, Olsen J, EuroMAP Group. Do pregnant women report use of dispensed medications? Epidemiology. 2001;12(5):497-501.
33. Ministry of health republic of Serbia. National health survey. Key findings. 2006. Available at: http://www.batut.org.rs/index.php? content=59. Accessed on 10 June 2012.